Summary (tl;dr)

Vitruvias Therapeutics has issued a nationwide recall for one lot of its 30 mg Thyroid Tablets due to concerns over potential superpotency, a risk the FDA has elevated to a Class I classification, indicating potential for serious health consequences or death.

Essential Background

Thyroid Tablets, USP, are a vital medication used to treat hypothyroidism, a condition characterized by an underactive thyroid gland that does not produce enough thyroid hormones. Derived from porcine thyroid glands, these tablets contain a precise balance of levothyroxine and liothyronine, hormones essential for metabolism and various bodily functions. The effectiveness and safety of thyroid treatment rely heavily on consistent and accurate dosing, as even slight variations in hormone levels can significantly impact patient health. The U.S. Food and Drug Administration (FDA) is responsible for ensuring the safety and efficacy of medications and issues recalls when products pose a risk to public health.

The Full Story

Vitruvias Therapeutics Inc., based in Auburn, Alabama, voluntarily initiated a recall of one specific lot (Lot No. 504950) of its Thyroid Tablets, USP 30 mg, on August 21, 2026. The FDA subsequently announced this recall on August 24, 2026. The recall was prompted by testing that confirmed the product's potential to be "superpotent," meaning the tablets could contain a higher dose of active thyroid hormone than specified on the label. This issue led the FDA to upgrade the recall to a Class I designation on September 22, 2026, which is the agency's most serious classification, reserved for situations where there is a reasonable probability that using the product could cause serious adverse health consequences or death. The affected lot was distributed nationwide across the United States to Vitruvias Therapeutics' direct accounts between January 31, 2025, and September 30, 2025, with approximately 1,955 bottles reportedly sold. Vitruvias Therapeutics has since ceased operations, with its products being transferred to H2-Pharma.

Why It Matters

The superpotency of thyroid medication can lead to hyperthyroidism, or an overactive thyroid, which can manifest in a range of adverse health effects. Symptoms may include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and heart rhythm disturbances. Certain populations, including the elderly, pregnant women, and infants, are at an elevated risk of severe complications if exposed to superpotent thyroid tablets over extended periods. For older adults, this can exacerbate cardiac health problems, while in pregnant women, overtreatment is linked to higher rates of fetal and maternal complications. Infants may experience negative effects on growth and development. Patients currently taking medication from the recalled lot are strongly advised not to discontinue use without first consulting their healthcare provider for guidance and a replacement prescription, highlighting the critical nature of these trending searches for public health and safety.

Geographic Location

• Auburn, Lee County, Alabama, United States (Vitruvias Therapeutics, Inc. initiating the recall)
• Washington, D.C., District of Columbia, United States (FDA classifying the recall as Class I)